A Phase II Trial of R115777, an Oral Farnesyltransferase Inhibitor (FTI) in Previously Untreated Patients With Advanced Urothelial Tract Transitional Cell Carcinoma
OBJECTIVES: I. Determine the efficacy of R115777 in terms of objective response in patients
with advanced transitional cell cancer of the urothelial tract. II. Determine the safety of
this treatment regimen in these patients. III. Determine the time to disease progression in
these patients with this treatment regimen.
OUTLINE: This is a multicenter study. Patients receive oral R115777 every 12 hours for 21
days in the absence of disease progression or unacceptable toxicity. Treatment repeats every
28 days for at least 2 courses. Patients are followed every 3 months for up to 5 years.
PROJECTED ACCRUAL: A total of 18-32 patients will be accrued for this study.
Primary Purpose: Treatment
John Seigne, MB
H. Lee Moffitt Cancer Center and Research Institute
United States: Federal Government
|H. Lee Moffitt Cancer Center and Research Institute||Tampa, Florida 33612|
|UCSF Cancer Center and Cancer Research Institute||San Francisco, California 94115-0128|